Akorn, Inc. and GeneraMedix Inc. Sign Commercial Manufacturing Supply Agreement

Akorn, Inc. (AMEX:AKN) today announced that it has
signed a Commercial Manufacturing Supply Agreement with GeneraMedix
Inc., a privately held pharmaceutical company that develops, markets
and sells generic injectable pharmaceutical products. Under the terms
of the Agreement, Akorn will manufacture injectable products in
finished dosage form for GeneraMedix, who will market these products
in the GeneraMedix label. The Agreement includes products currently
available from Akorn, as well as select injectable products from the
Akorn internal product development pipeline.
   Arthur S. Przybyl, President and Chief Executive Officer of Akorn
stated, "We are excited to enter into this strategic product supply
partnership with GeneraMedix. This partnership will allow us to expand
our existing market share and increase our contract sales revenues. We
believe that GeneraMedix and their executive management team have the
experience and infrastructure to successfully market these generic
products to the hospital and specialty pharmaceutical markets. We look
forward to a long-standing and successful relationship with
GeneraMedix."
   Ronald F. Quadrel, President and Chief Executive Officer of
GeneraMedix stated, "We are very pleased to enter into this strategic
relationship with Akorn as we continue to build our injectable product
portfolio. The addition of these products reinforces our long term
commitment to provide a broad range of generic injectable products to
hospitals, surgery centers and clinics."

   About Akorn, Inc.

   Akorn, Inc. manufactures and markets sterile specialty
pharmaceuticals. Akorn has manufacturing facilities located in
Decatur, Illinois and Somerset, New Jersey and markets and distributes
an extensive line of hospital and ophthalmic pharmaceuticals.
Additional information is available at the Company's website at
www.akorn.com.

   About GeneraMedix, Inc.

   GeneraMedix, Inc. is a pharmaceutical company offering high
quality injectable generic products to the hospital and specialty
markets. In addition to its products already marketed, GeneraMedix has
a significant number of injectable products under development, as well
as a number of products currently under FDA review. Headquartered in
Liberty Corner, New Jersey, the company was founded in July of 2004.
Additional information is available at the company's website at
www.generamedix.com.

   Materials in this press release may contain information that
includes or is based upon forward-looking statements within the
meaning of the Securities Litigation Reform Act of 1995.
Forward-looking statements give our expectations or forecasts of
future events. You can identify these statements by the fact that they
do not relate strictly to historical or current facts. They use words
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe," and other words and terms of similar meaning in
connection with a discussion of future operating or financial
performance. In particular, these include statements relating to
future steps we may take, prospective products, future performance or
results of current and anticipated products, sales efforts, expenses,
the outcome of contingencies such as legal proceedings, and financial
results.
   Any or all of our forward-looking statements here or in other
publications may turn out to be wrong. They can be affected by
inaccurate assumptions or by known or unknown risks and uncertainties.
Many such factors will be important in determining our actual future
results. Consequently, no forward-looking statement can be guaranteed.
Our actual results may vary materially, and there are not guarantees
about the performance of our stock.
   Any forward-looking statements represent our expectations or
forecasts only as of the date they were made and should not be relied
upon as representing our expectations or forecasts as of any
subsequent date. We undertake no obligation to correct or update any
forward-looking statements, whether as a result of new information,
future events or otherwise, even if our expectations or forecasts
change. You are advised, however, to consult any further disclosures
we make on related subjects in our reports filed with the SEC. In
particular, you should read the discussion in the section entitled
"Cautionary Statement Regarding Forward-Looking Statements" in our
most recent Annual Report on Form 10-K, as it may be updated in
subsequent reports filed with the SEC. That discussion covers certain
risks, uncertainties and possibly inaccurate assumptions that could
cause our actual results to differ materially from expected and
historical results. Such factors include, but are not limited to,
risks and uncertainties relating to the resolution of the FDA
compliance issues at our Decatur, Illinois manufacturing facility.
Other factors besides those listed there could also adversely affect
our results.